335063-47-3

Upstream product

• 911497-62-6 (4-{1-[5-(3-chloro-4-fluoro-phenyl)-pyrimidin-4-yl]-piperidin-4-yl}-5-methyl-1H-imidazol-2-yl)-(4-methoxy-phenyl)-diazene 
• 144432-85-9 3-chloro-4-fluorophenylboronic acid 
• 335063-18-8 5-(3-chloro-4-fluoro-phenyl)-4-[4-(5-methyl-1H-imidazol-4-yl)-piperidin-1-yl]-pyrimidine 

Relevant academic research and scientific papers

Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors

A series of potent inhibitors of the sodium hydrogen exchanger-1 (NHE-1) is described. Structure-activity relationships identified the 3-methyl-4-fluoro analog 9t as a highly potent (IC50 = 0.0065 μM) and selective (NHE-2/NHE-1 = 1400) non-acylguanidine NHE-1 inhibitor. Pharmacokinetic studies showed that compound 9t has an oral bioavailability of 52% and a plasma half life of 1.5 h in rats. Because of its promising potency, selectivity, and a good pharmacokinetic profile, compound 9t was selected for further studies.

Heterocyclic sodium/proton exchange inhibitors and method

Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C—R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl gorup, R1, R2, R3 and R4 are as defined herein, and where X is N. R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above heterocyclic derivatives.